Relapse in schizophrenia: costs, clinical outcomes and quality of life
Relapse in schizophrenia: costs, clinical outcomes and quality of life
复制标题
DOI：
10.1192/bjp.184.4.346
复制
发表时间：
2004-04-01
影响因子：
10.5
通讯作者：
Brugha, T
中科院分区：
文献类型：
--
作者：
Almond, S;Knapp, M;Brugha, T
背景复发是精神分裂症的最昂贵的方面之一。目的是比较成本，临床结果和生活质量的精神分裂症复发的患者与对照组谁没有复发。方法患者随机选择从目前的精神病病例负荷绘制的城市和郊区的莱斯特。使用参数和非参数检验，在过去6个月的复发状态的成本和结果的差异进行了检查，多变量分析被用来检查复发和costs.Results成本与复发的患者比那些非复发组的4倍以上。复发状态的临床和生活质量指标几乎没有统计学显著差异。多变量分析表明，复发和costs.Conclusions的一些显着的相关性较高的成本与复发将是利益的决策者面临困难的选择，新的，但更昂贵的治疗精神分裂症patients.Declaration的利益无。资金详情见鸣谢。
Background Relapse is one of the most costly aspects of schizophrenia.Aims To compare costs, clinical outcomes and quality of life for patients who experienced relapse in schizophrenia with a control group who did not relapse.Method Patients were randomly selected from current psychiatric case-loads drawn from urban and suburban areas of Leicester. Differences in costs and outcomes by relapse status in the previous 6 months were examined using parametric and non-parametric tests, and multivariate analysis was used to examine factors associated with relapse and costs.Results Costs for the patients who relapsed were over four times higher than those for the non-relapse group. There were few statistically significant differences in clinical and quality of life measures by relapse status. Multivariate analyses suggested some significant correlates of relapse and costs.Conclusions The higher costs associated with relapse will be of interest to policy-makers who face difficult choices concerning new but more expensive treatments for patients with schizophrenia.Declaration of interest None. Funding detailed in Acknowledgements.